VERU Veru Inc.

-0.02  -1%
Previous Close 2.33
Open 2.33
Price To Book 4.36
Market Cap 145,045,380
Shares 62,790,208
Volume 6,386
Short Ratio
Av. Daily Volume 231,004

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due summer 2019.
Zuclomiphene citrate
Hot flashes
NDA filing due summer 2020.
Tadalafil and Finasteride combo
Benign prostatic hyperplasia (BPH)
Phase 1b initiation announced January 22, 2019 with data due later in 2019.
VERU-111 (bisindole)
Prostate cancer

Latest News

  1. Options Traders Expect Huge Moves in Veru (VERU) Stock
  2. Veru Announces Successful Completion of Pre-NDA Meeting with FDA for TADFIN (Tadalafil 5mg and Finasteride 5mg) Combination for the Treatment of Benign Prostatic Hyperplasia
  3. Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA
  4. Veru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th
  5. Is Veru Inc.'s (NASDAQ:VERU) CEO Overpaid Relative To Its Peers?
  6. Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results
  7. Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th
  8. Veru (VERU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
  9. Introducing Veru (NASDAQ:VERU), The Stock That Tanked 81%
  10. Veru to Participate in Two Investor Conferences in March
  11. Have Insiders Been Buying Veru Inc. (NASDAQ:VERU) Shares This Year?
  12. Veru Reports Strong Fiscal 2019 First Quarter Financial Results
  13. Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium
  14. Earnings Preview: Veru (VERU) Q1 Earnings Expected to Decline
  15. Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th
  16. Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer
  17. Before You Buy Veru Inc. (NASDAQ:VERU), Consider Its Volatility
  18. Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019
  19. Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia
  20. Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter